Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.42 |
| ▸ | BRD4 | O60885 | 9/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.36 |
| ▸ | EP300 | Q09472 | 2/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16896809 | 0.91 | BRD4 (0.41) | FFAR1BRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL16905797 | 0.88 | BRD4 (0.42) | FFAR1BRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL20495558 | 0.87 | BRD4 (0.40) | FFAR1BRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL16896928 | 0.87 | BRD4 (0.40) | FFAR1BRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL18359630 | 0.86 | BRD4 (0.47) | FFAR1BRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL18359550 | 0.86 | BRD4 (0.40) | FFAR1BRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL16906139 | 0.86 | BRD4 (0.39) | FFAR1BRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL18359576 | 0.86 | BRD4 (0.40) | FFAR1BRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL18359525 | 0.85 | BRD4 (0.44) | FFAR1BRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL16896824 | 0.84 | BRD4 (0.39) | FFAR1BRD4CYP3A4CYP2C9BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312496-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-11-01 | — | — | US | claimed |
| US-20180312496-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-11-01 | — | — | US | disclosed |
| WO-2017001733-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312496-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD4, BRD2 | FFAR1 4032/4885BRD4 2/4885CYP3A4 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.